Cancer Genomics: Tumor Profiling Topical Map Library and SEO Content Plan
Use this Cancer Genomics: Tumor Profiling and Biomarkers topical map library entry to cover what is cancer genomics with topic clusters, pillar pages, article ideas, content briefs, prompt kits, and publishing order.
Built for SEOs, agencies, bloggers, and content teams that need a practical content plan for Google rankings, AI Overview eligibility, and LLM citation.
Use this map in your content workflow
Copy the article plan into a brief, spreadsheet, or client roadmap. The export keeps group, order, article title, intent, priority, target query, and summary together.
1. Foundations of Cancer Genomics and Tumor Profiling
Covers basic principles: why cancer is a genetic disease, the types of genomic alterations, tumor heterogeneity and evolution, and pre-analytic sample considerations — essential context for every other subtopic.
Cancer Genomics and Tumor Profiling: A Comprehensive Primer
Definitive introduction to cancer as a genomic disease and the rationale for tumor profiling. Explains mutation types, clonal dynamics, and sample issues so clinicians, researchers, and informed patients understand what tests reveal and their limitations.
Somatic vs Germline Mutations: What Clinicians and Patients Need to Know
Explains the biological difference between somatic and germline variants, clinical implications, and testing approaches to distinguish them.
Tumor Heterogeneity and Clonal Evolution Explained
Describes spatial and temporal heterogeneity, methods to detect subclones, and how evolution drives resistance and impacts interpretation.
Sample Types and Pre-Analytical Variables for Tumor Profiling (FFPE, Fresh, Blood)
Details how tissue handling, fixation, tumor cellularity, and blood collection affect test sensitivity and recommendations to optimize results.
Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI): Biology and Testing
Explains how TMB and MSI arise, their measurement methods, and clinical relevance for immunotherapy selection.
Cancer Genomics Glossary: Key Terms Clinicians and Researchers Must Know
Concise definitions of core genomics terms (VAF, LOD, CNV, fusion, hotspot, variant of uncertain significance) for quick reference.
2. Tumor Profiling Technologies and Assays
Compares sequencing and non-sequencing assays (WGS/WES/panels, RNA-seq, ctDNA, IHC/FISH/PCR), explaining analytic performance, use-cases, costs, and how to choose the right test.
Tumor Profiling Technologies: WGS, WES, Targeted Panels, and Liquid Biopsies — Choosing the Right Test
Comprehensive guide to available tumor profiling assays, their strengths and limitations, and decision framework for clinical and research scenarios. Covers technology, validation, performance metrics, and practical considerations like cost and turnaround.
Clinical vs Research Sequencing: When to Use WGS, WES, or Targeted Panels
Provides decision flowcharts and examples to select the optimal sequencing strategy based on clinical questions, sample quality, and budget.
Liquid Biopsy (ctDNA): How It Works, Clinical Indications, and Limitations
Explains ctDNA biology, assay types, sensitivity factors, approved indications, and interpretation guidelines including concordance with tissue.
Detecting Gene Fusions: RNAseq vs DNA-based Assays
Compares methods for fusion detection, strengths of RNA approaches, bait design, and clinical examples (ALK, ROS1, NTRK).
Assay Performance Metrics: Sensitivity, Specificity, Limit of Detection, and QC
Defines technical metrics used to evaluate assays and explains how they affect clinical interpretation, especially for low VAF variants.
Comparing Commercial Tumor Profiling Labs: FoundationOne, Guardant360, Tempus, and Others
Practical comparison of major commercial labs by assay composition, genes covered, clinical claims, turnaround time, and payer acceptance.
3. Clinical Biomarkers: Actionable, Predictive, and Prognostic
Catalogs established and emerging biomarkers across cancer types (EGFR, KRAS, BRAF, BRCA, MSI, TMB, PD-L1, NTRK etc.), their testing methods, and links to approved therapies or clinical trial strategies.
Key Genomic and Molecular Biomarkers in Oncology: Predictive, Prognostic, and Diagnostic
Authoritative catalog of clinically relevant biomarkers organized by cancer type and clinical use (diagnostic, prognostic, predictive). Includes companion diagnostics, evidence levels, and testing recommendations.
EGFR, ALK, ROS1, KRAS, BRAF in Lung Cancer: Testing and Treatment Implications
Detailed, clinically oriented review of actionable lung cancer biomarkers, testing algorithms, and associated targeted therapies and resistance mechanisms.
BRCA1/2 and Homologous Recombination Deficiency (HRD): Testing, PARP Inhibitors, and Somatic vs Germline
Explains BRCA biology, HRD assays, clinical trial evidence for PARP inhibitors, and how to interpret somatic vs germline BRCA findings.
Microsatellite Instability (MSI) and Mismatch Repair Deficiency: Testing Methods and Clinical Significance
Covers PCR, IHC, and NGS methods for MSI/MMR detection, implications for Lynch syndrome screening and immunotherapy
PD-L1, Tumor Mutational Burden (TMB) and Biomarkers for Immunotherapy
Summarizes assays, thresholds, clinical trial evidence and limitations of PD-L1 and TMB as predictors of immune checkpoint inhibitor response.
NTRK Fusions and Tumor-Agnostic Approvals: Testing and Clinical Management
Explains detection methods for NTRK fusions, approved tumor-agnostic therapies, and test selection strategies.
Concordance Between Liquid Biopsy Biomarkers and Tissue: Evidence and Practical Guidance
Reviews studies comparing ctDNA and tissue results, factors affecting concordance, and guidance for discordant findings.
4. Clinical Implementation: Interpretation and Reporting
Focuses on analysis pipelines, variant interpretation frameworks, standardized reporting, and how to integrate genomic reports into clinical decision-making and tumor boards.
Interpreting Tumor Genomic Reports: From Variant Calling to Clinical Action
A practical manual for clinicians and molecular pathologists on reading genomic reports, applying variant classification standards, linking evidence to action, and presenting cases in multidisciplinary tumor boards.
Variant Classification and Reporting Guidelines (AMP/ASCO/CAP and ACMG Explained)
Explains major variant classification systems, mapping evidence to actionability tiers, and examples for common variant types.
How to Read a Tumor Genomic Report: A Step-by-Step Clinical Guide
Walkthrough of a typical report with annotated screenshots (or examples), highlighting key fields clinicians must evaluate before making treatment decisions.
Integrating Genomic Data into Multidisciplinary Tumor Boards
Best practices for presenting genomic findings, crafting actionable recommendations, and documenting decisions for continuity of care.
Handling Secondary Germline Findings from Tumor Tests: Clinical Workflow and Patient Counseling
Guidance on identifying likely germline variants, confirming with germline testing, genetic counseling, and family cascade testing considerations.
AI and Clinical Decision Support for Tumor Report Interpretation
Survey of AI tools and knowledgebases that assist interpretation, their validation status, and cautions for clinical use.
5. Therapeutic Applications and Precision Oncology
Focuses on matching genomic results to therapies and trials: companion diagnostics, resistance mechanisms, tumor-agnostic approvals, and practical pathways for personalized treatment.
Precision Oncology: Matching Tumor Genomics to Targeted Therapies and Clinical Trials
Comprehensive resource on translating genomic findings into treatment: how companion diagnostics guide approvals, approaches to off-label use, managing resistance, and strategies for trial enrollment and outcome monitoring.
Companion Diagnostics and the Regulatory Landscape (FDA, CE, CLIA/CAP Considerations)
Explains what companion diagnostics are, regulatory pathways for approval, and how labs implement CDx claims into practice.
Managing Acquired Resistance: Case Studies (EGFR T790M, ALK Resistance Mutations, BRAF Reactivation)
Illustrative examples of common resistance pathways, testing after progression, and therapeutic strategies (new inhibitors, combinations).
How to Find and Match Patients to Clinical Trials: Tools, Filters, and Eligibility Strategies
Practical guide to trial matching platforms, key eligibility criteria derived from genomics, and optimizing referrals to academic centers.
Tumor-Agnostic Treatments and Basket Trials: Rationale and Clinical Examples
Explains the concept of tumor-agnostic approvals, examples (NTRK inhibitors, pembrolizumab for MSI-high), and how testing informs enrollment.
Real-World Evidence in Precision Oncology: Registries, Outcome Tracking, and Value
Covers registries and real-world data sources that capture outcomes from genomic-driven therapies and how payers and regulators use this evidence.
6. Data Resources, Knowledgebases, and Bioinformatics
Provides deep coverage of public cancer genomics datasets, clinical knowledgebases, annotation tools, and best-practice pipelines for research and clinical labs.
Cancer Genomics Data, Databases, and Bioinformatics: Tools for Analysis and Interpretation
Authoritative guide to the major public datasets, variant knowledgebases, and bioinformatics tools used for annotation and interpretation, plus best practices for clinical bioinformatics pipelines and reproducible analysis.
Using TCGA and cBioPortal for Cancer Research: A Practical Guide
Step-by-step walkthrough for accessing TCGA data and performing common exploratory analyses in cBioPortal with examples.
OncoKB, CIViC, ClinVar and Other Knowledgebases: How to Use Them for Clinical Decision-Making
Compares major knowledgebases, data models, evidence grading, and practical workflows to map variants to treatments.
Variant Annotation Pipelines: VEP vs ANNOVAR vs SnpEff and Best Practices
Technical comparison of annotation tools, typical pipeline architecture, and recommendations for clinical annotation.
Best Practices for Bioinformatics Pipelines in Clinical Labs: Validation, Versioning, and QA
Practical checklist for building, validating, and maintaining bioinformatics workflows that meet regulatory and clinical needs.
Accessing Open Cancer Genomics Datasets: GDC, EGA, and Controlled-Access Resources
How to request access, download data, and comply with restrictions for major public repositories used in cancer genomics research.
7. Ethics, Regulation, and Reimbursement
Addresses informed consent and privacy, regulatory frameworks for clinical tests, payer coverage and coding, and equity issues — critical for program implementation and patient trust.
Ethical, Regulatory, and Reimbursement Issues in Tumor Genomic Testing
Covers the non-technical but essential aspects of tumor genomic testing: consent, incidental germline findings, lab accreditation and FDA considerations, reimbursement policies, and strategies to improve equitable access.
Handling Incidental Germline Findings from Tumor Testing: Clinical Workflow and Consent
Operational guidance for consent language, confirmatory germline testing, genetic counseling referral, and family communication.
CLIA, CAP, and FDA: Regulatory Requirements for Clinical Tumor Genomic Tests
Explains laboratory accreditation, validation expectations, and scenarios where FDA-approved companion diagnostics are required versus laboratory-developed tests.
Reimbursement Landscape and Payer Coverage for Tumor Profiling: Coding and Appeals
Overview of common CPT codes, payer coverage patterns, evidence needed for approvals, and strategies for pre-authorization and appeals.
Equity, Access, and Global Disparities in Genomic Testing
Discusses barriers to access across geographies and socioeconomic groups and actionable steps programs can take to reduce disparities.
Content strategy and topical authority plan for Cancer Genomics: Tumor Profiling and Biomarkers
The recommended SEO content strategy for Cancer Genomics: Tumor Profiling and Biomarkers is the hub-and-spoke topical map model: one comprehensive pillar page on Cancer Genomics: Tumor Profiling and Biomarkers, supported by cluster articles each targeting a specific sub-topic. This gives Google the complete hub-and-spoke coverage it needs to rank your site as a topical authority on Cancer Genomics: Tumor Profiling and Biomarkers.
Pillar
Start with the core guide
Clusters
Follow grouped article themes
Priority
Publish strongest opportunities first
Sequence
Use the recommended order
Search intent coverage across Cancer Genomics: Tumor Profiling and Biomarkers
This topical map covers the full intent mix needed to build authority, not just one article type.
Entities and concepts to cover in Cancer Genomics: Tumor Profiling and Biomarkers
Publishing order
Start with the pillar page, then publish the high-priority articles first to establish coverage around what is cancer genomics faster.
Use the recommended sequence as the content calendar foundation.